Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.

Bórquez A, Guanira JV, Revill P, Caballero P, Silva-Santisteban A, Kelly S, Salazar X, Bracamonte P, Minaya P, Hallett TB, Cáceres CF.

Lancet Public Health. 2019 Jan 22. pii: S2468-2667(18)30236-6. doi: 10.1016/S2468-2667(18)30236-6. [Epub ahead of print]

2.

Appraising the value of evidence generation activities: an HIV modelling study.

Woods B, Rothery C, Anderson SJ, Eaton JW, Revill P, Hallett TB, Claxton K.

BMJ Glob Health. 2018 Dec 7;3(6):e000488. doi: 10.1136/bmjgh-2017-000488. eCollection 2018.

3.

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.

Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren JD, De Luca A, Pillay D, Mellors J, Cambiano V, Bansi-Matharu L, Nakagawa F, Kalua T, Jahn A, Apollo T, Mugurungi O, Clayden P, Gupta RK, Barnabas R, Revill P, Cohn J, Bertagnolio S, Calmy A.

Lancet HIV. 2019 Feb;6(2):e116-e127. doi: 10.1016/S2352-3018(18)30317-5. Epub 2018 Nov 29.

4.

Fresh Money for Health? The (False?) Promise of "Innovative Financing" for Health in Malawi.

Chansa C, Mwase T, Matsebula TC, Kandoole P, Revill P, Makumba JB, Lindelow M.

Health Syst Reform. 2018;4(4):324-335. doi: 10.1080/23288604.2018.1506643. Epub 2018 Oct 29.

PMID:
30373454
5.

Economic Analysis of Vaccination Programs.

Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL.

Value Health. 2018 Oct;21(10):1133-1149. doi: 10.1016/j.jval.2018.08.005. Review.

PMID:
30314613
6.

Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood.

McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, McKeating JA, Matthews PC.

Gastroenterology. 2019 Jan;156(2):384-399. doi: 10.1053/j.gastro.2018.07.058. Epub 2018 Sep 27. Review.

7.

Potential effect of household contact management on childhood tuberculosis: a mathematical modelling study.

Dodd PJ, Yuen CM, Becerra MC, Revill P, Jenkins HE, Seddon JA.

Lancet Glob Health. 2018 Dec;6(12):e1329-e1338. doi: 10.1016/S2214-109X(18)30401-7. Epub 2018 Sep 25.

8.

Cost-Effectiveness of Interventions to Prevent HIV Acquisition.

Garnett GP, Krishnaratne S, Harris KL, Hallett TB, Santos M, Enstone JE, Hensen B, Dallabetta G, Revill P, Gregson SAJ, Hargreaves JR.

In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 7.

9.

Molecular characterization of hepatitis B virus (HBV) in African children living in Australia identifies genotypes and variants associated with poor clinical outcome.

Bannister EG, Yuen L, Littlejohn M, Edwards R, Sozzi V, Colledge D, Li X, Locarnini S, Hardikar W, Revill PA.

J Gen Virol. 2018 Aug;99(8):1103-1114. doi: 10.1099/jgv.0.001086. Epub 2018 Jun 22.

PMID:
29932395
10.

In vitro studies identify a low replication phenotype for hepatitis B virus genotype H generally associated with occult HBV and less severe liver disease.

Sozzi V, Shen F, Chen J, Colledge D, Jackson K, Locarnini S, Yuan Z, Revill PA.

Virology. 2018 Jun;519:190-196. doi: 10.1016/j.virol.2018.04.015. Epub 2018 May 4.

PMID:
29734042
11.

Supporting the development of a health benefits package in Malawi.

Ochalek J, Revill P, Manthalu G, McGuire F, Nkhoma D, Rollinger A, Sculpher M, Claxton K.

BMJ Glob Health. 2018 Apr 9;3(2):e000607. doi: 10.1136/bmjgh-2017-000607. eCollection 2018.

12.

ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.

Wong D, Littlejohn M, Edwards R, Jackson K, Revill P, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti-Ferret M, Janssen H, Gane E, Locarnini S, Thompson A.

Liver Int. 2018 Oct;38(10):1760-1769. doi: 10.1111/liv.13716. Epub 2018 Mar 6.

PMID:
29427368
13.

Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries.

Tierrablanca LE, Ochalek J, Ford D, Babiker A, Gibb D, Butler K, Turkova A, Griffin S, Revill P; BREATHER (PENTA 16) Trial Group.

Medicine (Baltimore). 2018 Feb;97(5):e9698. doi: 10.1097/MD.0000000000009698. Erratum in: Medicine (Baltimore). 2018 Feb;97(7):e0012.

14.

Patient-level benefits associated with decentralization of antiretroviral therapy services to primary health facilities in Malawi and Uganda.

Abongomera G, Chiwaula L, Revill P, Mabugu T, Tumwesige E, Nkhata M, Cataldo F, van Oosterhout J, Colebunders R, Chan AK, Kityo C, Gilks C, Hakim J, Seeley J, Gibb DM, Ford D.

Int Health. 2018 Jan 1;10(1):8-19. doi: 10.1093/inthealth/ihx061.

15.

Reflecting the real value of health care resources in modelling and cost-effectiveness studies-The example of viral load informed differentiated care.

Revill P, Walker S, Cambiano V, Phillips A, Sculpher MJ.

PLoS One. 2018 Jan 2;13(1):e0190283. doi: 10.1371/journal.pone.0190283. eCollection 2018.

16.

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.

Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, Rinke de Wit T, Sigaloff K, Havlir D, Kuritzkes DR, Pozniak A, van de Vijver D, Vitoria M, Wainberg MA, Raizes E, Bertagnolio S; Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa.

Lancet HIV. 2018 Mar;5(3):e146-e154. doi: 10.1016/S2352-3018(17)30190-X. Epub 2017 Nov 22.

17.

Cost-effectiveness of routine viral load monitoring in low- and middle-income countries: a systematic review.

Barnabas RV, Revill P, Tan N, Phillips A.

J Int AIDS Soc. 2017 Nov;20 Suppl 7. doi: 10.1002/jia2.25006. Review.

18.

Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype.

Shen F, Li Y, Wang Y, Sozzi V, Revill PA, Liu J, Gao L, Yang G, Lu M, Sutter K, Dittmer U, Chen J, Yuan Z.

Hepatology. 2018 Apr;67(4):1237-1252. doi: 10.1002/hep.29609. Epub 2018 Feb 22.

PMID:
29059468
19.

Pre-exposure prophylaxis is cost-effective for HIV in the UK.

Revill P, Dwyer E.

Lancet Infect Dis. 2018 Jan;18(1):10-11. doi: 10.1016/S1473-3099(17)30594-7. Epub 2017 Oct 17. No abstract available.

20.

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.

Wong D, Littlejohn M, Yuen L, Jackson K, Mason H, Bayliss J, Rosenberg G, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti M, Janssen HLA, Gane E, Locarnini S, Thompson A, Revill PA.

Aliment Pharmacol Ther. 2018 Jan;47(1):114-122. doi: 10.1111/apt.14362. Epub 2017 Oct 11.

PMID:
29023803
21.

Causal effects of HIV on employment status in low-income settings.

Ochalek J, Revill P, van den Berg B.

Econ Hum Biol. 2017 Nov;27(Pt A):248-260. doi: 10.1016/j.ehb.2017.09.001. Epub 2017 Sep 8.

PMID:
28930699
22.

Hepatitis B among immigrants from Myanmar: Genotypes and their clinical relevance.

Schulz TR, Edwards R, Thurnheer MC, Yuen L, Littlejohn M, Revill P, Chu M, Tanyeri F, Wade A, Biggs BA, Sasadeusz J.

J Med Virol. 2018 Feb;90(2):271-276. doi: 10.1002/jmv.24939. Epub 2017 Sep 26.

PMID:
28885711
23.

A research agenda for curing chronic hepatitis B virus infection.

Alter H, Block T, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Chisari FV, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten T, Guo H, Guo JT, Hoshida Y, Hu J, Kowdley KV, Li W, Liang J, Locarnini S, Lok AS, Mason W, McMahon B, Mehta A, Perrillo R, Revill P, Rice CM, Rinaudo J, Schinazi R, Seeger C, Shetty K, Tavis J, Zoulim F.

Hepatology. 2018 Mar;67(3):1127-1131. doi: 10.1002/hep.29509. Epub 2018 Jan 24. No abstract available.

24.

Taxonomy of the order Mononegavirales: update 2017.

Amarasinghe GK, Bào Y, Basler CF, Bavari S, Beer M, Bejerman N, Blasdell KR, Bochnowski A, Briese T, Bukreyev A, Calisher CH, Chandran K, Collins PL, Dietzgen RG, Dolnik O, Dürrwald R, Dye JM, Easton AJ, Ebihara H, Fang Q, Formenty P, Fouchier RAM, Ghedin E, Harding RM, Hewson R, Higgins CM, Hong J, Horie M, James AP, Jiāng D, Kobinger GP, Kondo H, Kurath G, Lamb RA, Lee B, Leroy EM, Li M, Maisner A, Mühlberger E, Netesov SV, Nowotny N, Patterson JL, Payne SL, Paweska JT, Pearson MN, Randall RE, Revill PA, Rima BK, Rota P, Rubbenstroth D, Schwemmle M, Smither SJ, Song Q, Stone DM, Takada A, Terregino C, Tesh RB, Tomonaga K, Tordo N, Towner JS, Vasilakis N, Volchkov VE, Wahl-Jensen V, Walker PJ, Wang B, Wang D, Wang F, Wang LF, Werren JH, Whitfield AE, Yan Z, Ye G, Kuhn JH.

Arch Virol. 2017 Aug;162(8):2493-2504. doi: 10.1007/s00705-017-3311-7. Epub 2017 Apr 7.

25.

Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys.

Abongomera G, Kiwuwa-Muyingo S, Revill P, Chiwaula L, Mabugu T, Phillips AN, Katabira E, Chan AK, Gilks C, Musiime V, Hakim J, Kityo C, Colebunders R, Gibb DM, Seeley J, Ford D; Lablite Project Team.

Int Health. 2017 Mar 1;9(2):91-99. doi: 10.1093/inthealth/ihx006.

26.

Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa.

Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, Doherty M, Revill P, Bertagnolio S.

J Infect Dis. 2017 May 1;215(9):1362-1365. doi: 10.1093/infdis/jix089. Erratum in: J Infect Dis. 2017 Nov 15;216(8):1048.

27.

The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde.

Valaydon Z, Pellegrini M, Thompson A, Desmond P, Revill P, Ebert G.

Clin Transl Immunology. 2016 Dec 9;5(12):e115. doi: 10.1038/cti.2016.68. eCollection 2016 Dec. Review.

28.

Factors influencing job preferences of health workers providing obstetric care: results from discrete choice experiments in Malawi, Mozambique and Tanzania.

McAuliffe E, Galligan M, Revill P, Kamwendo F, Sidat M, Masanja H, de Pinho H, Araujo E.

Global Health. 2016 Dec 20;12(1):86. doi: 10.1186/s12992-016-0222-4.

29.

Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.

Woods B, Revill P, Sculpher M, Claxton K.

Value Health. 2016 Dec;19(8):929-935. doi: 10.1016/j.jval.2016.02.017.

30.

The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought.

Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns JA, Teerawattananon Y, Asfaw E, Lopert R, Culyer AJ, Walker DG.

Value Health. 2016 Dec;19(8):921-928. doi: 10.1016/j.jval.2016.04.015.

31.

Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa.

Phillips AN, Cambiano V, Nakagawa F, Bansi-Matharu L, Sow PS, Ehrenkranz P, Ford D, Mugurungi O, Apollo T, Murungu J, Bangsberg DR, Revill P.

PLoS One. 2016 Dec 15;11(12):e0167654. doi: 10.1371/journal.pone.0167654. eCollection 2016.

32.

Reply: 'More viral mutants, less HBsAg clearance? One size may not fit all'.

Thompson A, Locarnini S, Revill P.

Gut. 2017 Aug;66(8):1534-1535. doi: 10.1136/gutjnl-2016-313287. Epub 2016 Nov 24. No abstract available.

PMID:
27884921
33.

Measuring and Valuing Informal Care for Economic Evaluation of HIV/AIDS Interventions: Methods and Application in Malawi.

Chiwaula LS, Revill P, Ford D, Nkhata M, Mabugu T, Hakim J, Kityo C, Chan AK, Cataldo F, Gibb D, van den Berg B; Lablite Project Team.

Value Health Reg Issues. 2016 Sep;10:73-78. doi: 10.1016/j.vhri.2016.08.002. Epub 2016 Sep 16.

34.

Genotypic profiles of hepatitis B in African immigrants and their clinical relevance.

Thurnheer MC, Edwards R, Schulz TR, Yuen L, Littlejohn M, Revill P, Bannister E, Chu M, Tanyeri F, Wade A, Biggs BA, Sasadeusz J.

J Med Virol. 2017 Jun;89(6):1000-1007. doi: 10.1002/jmv.24732. Epub 2016 Dec 9.

PMID:
27862013
35.

Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline study.

Nkhata MJ, Muzambi M, Ford D, Chan AK, Abongomera G, Namata H, Mambule I, South A, Revill P, Grundy C, Mabugu T, Chiwaula L, Hakim J, Kityo C, Reid A, Katabira E, Sodhi S, Gilks CF, Gibb DM, Seeley J, Cataldo F; Lablite team.

BMC Health Serv Res. 2016 Nov 16;16(1):660.

36.

Ethics and hepatitis B cure research.

Sugarman J, Revill P, Zoulim F, Yazdanpanah Y, Janssen HL, Lim SG, Lewin SR.

Gut. 2017 Mar;66(3):389-392. doi: 10.1136/gutjnl-2016-313009. Epub 2016 Nov 14. No abstract available.

PMID:
27849559
37.

In Vitro Studies Show that Sequence Variability Contributes to Marked Variation in Hepatitis B Virus Replication, Protein Expression, and Function Observed across Genotypes.

Sozzi V, Walsh R, Littlejohn M, Colledge D, Jackson K, Warner N, Yuen L, Locarnini SA, Revill PA.

J Virol. 2016 Oct 28;90(22):10054-10064. Print 2016 Nov 15.

38.

Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).

Revill P, Locarnini S.

Curr Opin Pharmacol. 2016 Oct;30:144-150. doi: 10.1016/j.coph.2016.08.015. Review.

PMID:
27639371
39.

Point-of-Care Viral Load Testing for Sub-Saharan Africa: Informing a Target Product Profile.

Phillips AN, Cambiano V, Nakagawa F, Ford D, Apollo T, Murungu J, Rousseau C, Garnett G, Ehrenkranz P, Bansi-Matharu L, Vojnov L, Katz Z, Peeling R, Revill P.

Open Forum Infect Dis. 2016 Jul 29;3(3):ofw161. eCollection 2016 Sep.

40.

Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.

Bayliss J, Yuen L, Rosenberg G, Wong D, Littlejohn M, Jackson K, Gaggar A, Kitrinos KM, Subramanian GM, Marcellin P, Buti M, Janssen HLA, Gane E, Sozzi V, Colledge D, Hammond R, Edwards R, Locarnini S, Thompson A, Revill PA.

Gut. 2017 Nov;66(11):2013-2023. doi: 10.1136/gutjnl-2015-309300. Epub 2016 Aug 17.

PMID:
27534671
41.

Erratum to: Complete genome sequence of Colocasia bobone disease-associated virus, a putative cytorhabdovirus infecting taro.

Higgins CM, Bejerman N, Li M, James AP, Dietzgen RG, Pearson MN, Revill PA, Harding RM.

Arch Virol. 2016 Oct;161(10):2951-2952. No abstract available.

PMID:
27488879
42.

Single-Molecule Sequencing Reveals Complex Genome Variation of Hepatitis B Virus during 15 Years of Chronic Infection following Liver Transplantation.

Betz-Stablein BD, Töpfer A, Littlejohn M, Yuen L, Colledge D, Sozzi V, Angus P, Thompson A, Revill P, Beerenwinkel N, Warner N, Luciani F.

J Virol. 2016 Jul 27;90(16):7171-7183. doi: 10.1128/JVI.00243-16. Print 2016 Aug 15.

43.

Overview of hepatitis B viral replication and genetic variability.

Tong S, Revill P.

J Hepatol. 2016 Apr;64(1 Suppl):S4-S16. doi: 10.1016/j.jhep.2016.01.027. Review.

44.

Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa.

Phillips AN, Cambiano V, Revill P, Nakagawa F, Lundgren JD, Bansi-Matharu L, Mabugu T, Sculpher M, Garnett G, Staprans S, Becker S, Murungu J, Lewin SR, Deeks SG, Hallett TB.

J Infect Dis. 2016 Jul 1;214(1):73-9. doi: 10.1093/infdis/jiw120. Epub 2016 Mar 30.

45.

Global strategies are required to cure and eliminate HBV infection.

Revill P, Testoni B, Locarnini S, Zoulim F.

Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):239-48. doi: 10.1038/nrgastro.2016.7. Epub 2016 Feb 24. Review.

PMID:
26907881
46.

New perspectives on the hepatitis B virus life cycle in the human liver.

Revill PA, Locarnini SA.

J Clin Invest. 2016 Mar 1;126(3):833-6. doi: 10.1172/JCI86650. Epub 2016 Feb 22.

47.

Complete genome sequence of Colocasia bobone disease-associated virus, a putative cytorhabdovirus infecting taro.

Higgins CM, Bejerman N, Li M, James AP, Dietzgen RG, Pearson MN, Revill PA, Harding RM.

Arch Virol. 2016 Mar;161(3):745-8. doi: 10.1007/s00705-015-2713-7. Epub 2015 Dec 21. Erratum in: Arch Virol. 2016 Oct;161(10):2951-2.

PMID:
26687584
48.

Sustainable HIV treatment in Africa through viral-load-informed differentiated care.

Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa, Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, Bonner K, Rousseau C, Garnett G, Cambiano V, Nakagawa F, Ford D, Bansi-Matharu L, Miners A, Lundgren JD, Eaton JW, Parkes-Ratanshi R, Katz Z, Maman D, Ford N, Vitoria M, Doherty M, Dowdy D, Nichols B, Murtagh M, Wareham M, Palamountain KM, Chakanyuka Musanhu C, Stevens W, Katzenstein D, Ciaranello A, Barnabas R, Braithwaite RS, Bendavid E, Nathoo KJ, van de Vijver D, Wilson DP, Holmes C, Bershteyn A, Walker S, Raizes E, Jani I, Nelson LJ, Peeling R, Terris-Prestholt F, Murungu J, Mutasa-Apollo T, Hallett TB, Revill P.

Nature. 2015 Dec 3;528(7580):S68-76. doi: 10.1038/nature16046.

49.

Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda.

Abongomera G, Kiwuwa-Muyingo S, Revill P, Chiwaula L, Mabugu T, Phillips A, Katabira E, Musiime V, Gilks C, Chan A, Hakim J, Colebunders R, Kityo C, Gibb DM, Seeley J, Ford D; Lablite Project Team.

BMC Health Serv Res. 2015 Nov 28;15:527. doi: 10.1186/s12913-015-1194-4.

50.

Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients.

Visvanathan K, Lang T, Ryan K, Wilson R, Skinner NA, Thompson AJ, Ahn SH, Weilert F, Abbott W, Gane E, Colledge D, Li K, Locarnini S, Mansell A, Revill PA.

J Viral Hepat. 2016 Mar;23(3):170-9. doi: 10.1111/jvh.12477. Epub 2015 Oct 5.

PMID:
26436722

Supplemental Content

Loading ...
Support Center